Related Experiment Video

Updated: May 28, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Summary of presentation from the targeted therapy in lung cancer meeting

Ramaswamy Govindan1

  • 1Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA. rgovinda@dom.wustl.edu

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|October 19, 2011
PubMed

Insights

Researchers are exploring new molecularly targeted therapies for advanced non-small cell lung cancer. Experts convened to discuss progress and challenges in this rapidly evolving field, fostering collaboration and new ideas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Advancements in identifying new molecular pathways for cancer treatment.
  • Ongoing clinical trials for novel therapeutic agents in advanced non-small cell lung cancer (NSCLC).
  • The need for collaborative discussions among experts to address challenges and progress in NSCLC treatment.

Purpose of the Study:

  • To summarize recent developments in molecularly targeted therapy for non-small cell lung cancer.
  • To provide insights from leading experts in the field.
  • To foster collaboration and idea exchange among researchers and clinicians.

Main Methods:

  • Summaries of presentations from a conference on molecularly targeted therapy in non-small cell lung cancer.
  • Expert-led discussions on current research and clinical trial outcomes.
  • Compilation of brief reports from leading lung cancer specialists.

Main Results:

  • Identification of new therapeutic pathways for advanced non-small cell lung cancer.
  • Evaluation of novel agents in various stages of clinical trials.
  • Mixed results, with progress in some areas and setbacks in others.

Conclusions:

  • Molecularly targeted therapy holds promise for non-small cell lung cancer treatment.
  • Continued research and collaboration are crucial for overcoming challenges.
  • Expert meetings serve as vital platforms for advancing the field.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...